Hexarelin
Hexarelin, explained.
Hexarelin is one of the more potent of the older growth-hormone-releasing peptides, and one also studied for activity on heart tissue. This page is a neutral, educational overview of what it is and how it has been studied.
Educational only — not medical advice. Consult a qualified licensed provider.
Hexarelin is a synthetic six-amino-acid growth-hormone-releasing peptide (GHRP), a ghrelin-receptor agonist developed in the 1990s and studied for its ability to trigger a pulse of the body's own growth hormone. It has also been investigated for heart-tissue effects through the CD36 receptor. It is research-only and not FDA-approved. This page is neutral educational information, not medical advice.
What Hexarelin is
Hexarelin is a synthetic hexapeptide — a chain of six amino acids — in the growth-hormone-releasing peptide (GHRP) family, the same class as GHRP-6 and ipamorelin. It was designed in the early 1990s as a chemically modified analog of GHRP-6 and is widely described as one of the most potent GH secretagogues in its class. Its activity comes from acting as a ghrelin mimetic at the GHS-R1a receptor, the same receptor the body's own hunger hormone ghrelin uses. Hexarelin reached Phase II human trials for growth-hormone deficiency and congestive heart failure in the late 1990s, but development was never completed and it was never approved or marketed as a drug. Today it exists as a research compound, not an approved medicine.
How Hexarelin is thought to work
Hexarelin has two distinct mechanisms, which is what makes it unusual in its class. First, like other GHRPs, it binds the GHS-R1a receptor in the pituitary and hypothalamus and stimulates the release of stored growth hormone — a pulse that is independent of, and additive to, the GHRH pathway, so it can stimulate cells that no longer respond to GHRH. Second, hexarelin binds CD36, a scavenger receptor found on heart and vascular tissue. The CD36 route is largely independent of growth hormone and is the basis of the cardiovascular research interest: in animal models it activates survival signaling (PI3K/Akt) in heart muscle. One well-documented quirk reported in the literature is desensitization — in a human study the GH response fell progressively over several weeks of continued administration and then recovered after the peptide was stopped.
Areas of research interest
- Its capacity to stimulate a pulse of the body's own growth hormone
- Body-composition questions tied to GH physiology, studied at a preclinical level
- Associations between GH pulses and recovery or sleep, studied anecdotally and in small studies
- Cardiovascular signaling via the CD36 pathway — largely preclinical/animal work and a few very small human studies, not established therapy
- Comparisons of potency and selectivity against gentler GHRPs such as ipamorelin
Legal & regulatory status
Hexarelin is not approved by the FDA for any indication. It reached Phase II human trials in the 1990s for growth-hormone deficiency and congestive heart failure, but development was never completed and it was never approved or marketed as a medicine. Today it is sold and handled as a research-only compound, not a supplement or an approved drug, and the research-chemical market in which it circulates is unregulated. This page is educational information about what hexarelin is and how it has been studied — it is not medical advice and not an endorsement of use. Anyone with questions about peptides and their own health should consult a qualified licensed provider.
Safety & what the research shows
Hexarelin is not an approved drug and its long-term safety in humans has not been established; most of what is known comes from small, short studies and preclinical work. In the literature, the effects most commonly described mirror the GHRP class — because it mimics ghrelin — and include increased hunger, water retention, tingling or numbness, flushing, head-rush sensations, and lethargy. Unlike the more selective ipamorelin, hexarelin has been documented to raise cortisol, ACTH, and prolactin to some degree, with one human study reporting activation of the stress (HPA) axis, likely via vasopressin — so its profile is less selective than newer GHRPs. Desensitization of the GH response with continued daily use is well documented in the literature. As a GH secretagogue it is also studied in the context of the general questions tied to growth-hormone elevation, such as effects on blood sugar and insulin sensitivity and the theoretical concern of stimulating existing tumors. The cardiovascular signals seen via CD36 come largely from animal models and a handful of very small human studies — they are research signals, not proven treatments. This is educational information, not medical advice; anyone with questions should talk to a qualified licensed provider.
Hexarelin vs related peptides
| Hexarelin | Ipamorelin | GHRP-6 | |
|---|---|---|---|
| Class | GHRP (hexapeptide) | GHRP (pentapeptide) | GHRP (hexapeptide) |
| GH potency | Very high (most potent of the three) | Moderate | Moderate |
| Selectivity | Lower — raises cortisol/prolactin/ACTH | High — minimal cortisol/prolactin | Lower — raises cortisol/prolactin, strong hunger |
| Hunger effect | Mild-to-moderate | Minimal | Strong (signature trait) |
| CD36 heart effect | Yes — distinct cardiovascular research interest | No | Limited |
| Desensitization | Notable with continuous use | Less pronounced | Notable with continuous use |
How PepEasy helps
Learn it
Get clear, plain-language explanations of Hexarelin — what it is, how it is classified, how it differs from gentler GHRPs, and what the research does and does not show.
Understand the science
See how hexarelin has been studied in the literature, where the evidence is preclinical or limited, and why its regulatory status matters — all framed as neutral education, not medical advice.
Frequently asked
What are Hexarelin's reported side effects?+
Effects described in the literature mirror the GHRP class: increased hunger, water retention, tingling, flushing, head-rush, and lethargy. Unlike ipamorelin, hexarelin has been reported to raise cortisol, ACTH, and prolactin, and its GH response desensitizes with continuous use. Long-term human safety is not established.
Is Hexarelin a steroid?+
No. Hexarelin is a peptide — a six-amino-acid chain — not an anabolic steroid. It is described in the literature as a secretagogue that acts on the ghrelin (GHS-R1a) receptor to signal the pituitary to release stored growth hormone, rather than introducing an external hormone.
How is Hexarelin different from ipamorelin?+
Both are GHRPs, but hexarelin is described as markedly more potent and less selective — it raises cortisol and prolactin and desensitizes with continued use, where ipamorelin is characterized as more selective. A distinguishing feature noted for hexarelin is its binding of the CD36 receptor on heart tissue, which ipamorelin does not.
Is Hexarelin FDA approved?+
No. Hexarelin reached Phase II human trials in the 1990s but was never completed, approved, or marketed. It is sold as a research-only compound and is not approved for human use for any indication. Treat it accordingly and consult a qualified clinician.
Everything peptides, made easy.
Join PepEasy and get the tools, the knowledge, and the care — in one place.
Explore more